LON:AREC

Arecor Therapeutics Interim Earnings Results & Report

Arecor Therapeutics logo
GBX 72 -4.00 (-5.26%)
As of 11/20/2026 09:56 AM Eastern

Arecor Therapeutics reported Interim earnings on October 1, 2026. The company reported EPS of -GBX 8.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

Arecor Therapeutics EPS Results

Actual EPS
-GBX 8
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Arecor Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Arecor Therapeutics Interim Earnings FAQ

Arecor Therapeutics (LON:AREC) reported earnings of -GBX 8 per share for Interim. The report was announced on Thursday, October 1, 2026.

Arecor Therapeutics Earnings Headlines

Arecor Therapeutics PLC
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
Patents for concentrated ultra-rapid insulins
Arecor Therapeutics adds patents as it eyes $3 billion US market
See More Arecor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arecor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arecor Therapeutics and other key companies, straight to your email.

About Arecor Therapeutics

Arecor Therapeutics (LON:AREC) (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.

View Arecor Therapeutics Profile